Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

Mens Novo Nordisk tjener milliarder på fedmemedicin, bliver medicinalgigantens amerikanske medarbejderes pension investeret i junkfood Mens Novo Nordisk tjener styrtende på vægttabsmedicin ...